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Expression of the proapoptotic protein Bax under the control of a GAL10 promoter in Saccharomyces
cerevisiae resulted in galactose-inducible cell death. Immunofluorescence studies suggested that Bax is prin-
cipally associated with mitochondria in yeast cells. Removal of the carboxyl-terminal transmembrane (TM)
domain from Bax [creating Bax (DTM)] prevented targeting to mitochondrial and completely abolished cyto-
toxic function in yeast cells, suggesting that membrane targeting is crucial for Bax-mediated lethality. Fusing
a TM domain from Mas70p, a yeast mitochondrial outer membrane protein, to Bax (DTM) restored targeting
to mitochondria and cytotoxic function in yeast cells. Deletion of four well-conserved amino acids (IGDE) from
the BH3 domain of Bax ablated its ability to homodimerize and completely abrogated lethality in yeast cells.
In contrast, several Bax mutants which retained ability to homodimerize (DBH1, DBH2, and D1-58) also
retained at least partial lethal function in yeast cells. In coimmunoprecipitation experiments, expression of the
wild-type Bax protein in Rat-1 fibroblasts and 293 epithelial cells induced apoptosis, whereas the Bax (DIGDE)
mutant failed to induce apoptosis and did not associate with endogenous wild-type Bax protein. In contrast to
yeast cells, Bax (DTM) protein retained cytotoxic function in Rat-1 and 293 cells, was targeted largely to
mitochondria, and dimerized with endogenous Bax in mammalian cells. Thus, the dimerization-mediating BH3
domain and targeting to mitochondrial membranes appear to be essential for the cytotoxic function of Bax in
both yeast and mammalian cells.
Cell death plays an important role in many physiological
processes, including removal of redundant cells during devel-
opment, elimination of autoreactive lymphocytes from the im-
mune system, and tissue homeostasis in essentially all organs in
which cell division occurs (reviewed in references 12, 16, 58, 76,
and 80). Dysregulation of normal cell death mechanisms also
figures prominently in several diseases (reviewed in references
7, 32, 58, 59, 73, and 80). In many but not all cases, the cell
deaths that occur under normal physiological circumstances
involve characteristic morphological changes that are broadly
known as apoptosis. These morphological changes, which in-
clude nuclear fragmentation, chromatin condensation, cell
shrinkage, plasma membrane blebbing, and budding off of
cellular fragments, are distinct from the cellular and organellar
swelling and rupture that are typically seen in the setting of
necrosis (82, 83).
Among the more prominent regulators of apoptosis are
members of the Bcl-2 family of proteins. These proteins appear
to regulate a distal step in an evolutionarily conserved pathway
for physiological cell death and apoptosis, with some members
functioning as suppressors of apoptosis and others function-
ing as promoters of cell death (reviewed in references 53, 56,
58, and 75). Interestingly, though best known for its ability to
regulate apoptotic cell death, the antiapoptotic protein Bcl-2
has also been shown to be capable of suppressing necrotic cell
death under some circumstances (28, 29, 66, 69), suggesting
that some overlap exists in the cell death mechanisms which
lead to apoptosis and necrosis and implying that Bcl-2 family
proteins can potentially influence both of these types of cellu-
lar demise. At present, the biochemical mechanisms by which
Bcl-2 family proteins control cell life and death remain enig-
matic, principally because their predicted amino acid se-
quences have no significant homology with other proteins. The
nuclear magnetic resonance and X-ray crystal structures of the
Bcl-2 family protein Bcl-XL, however, suggest structural simi-
larity to bacterial toxin, pore-forming proteins such as the B
subunit of diphtheria toxin, and colicin A (50). The functions
of Bcl-2 family proteins appear to be dependent at least in part
on their ability to interact with each other through a complex
network of homo- and heterodimers (4, 19, 55, 61, 65, 86).
In this report, we have focused on a structure-function anal-
ysis of the Bax-a protein, a 21-kDa proapoptotic member of
the Bcl-2 protein family (55). Bax-a is widely expressed in
mammalian tissues (34). Loss of Bax function through gene
disruption in mice leads to hyperplasias in several tissues in
vivo, suggesting a need for Bax in some of the cell turnover
mechanisms required for normal tissue homeostasis (31). Ex-
pression of Bax is selectively induced in vivo by g irradiation in
radiosensitive tissues that experience apoptotic cell death after
genotoxic injury (30). Moreover, the BAX gene is a direct
transcriptional target of p53 (47), suggesting an important role
of Bax in radio- and chemoresponses of tumors (89). Consis-
tent with this idea, reductions in Bax protein levels which occur
in about one-third of metastatic breast cancers have been cor-
related with poor patient responses to combination chemo-
therapy and shorter overall survival (33). Striking elevations in
Bax protein levels are also induced in several types of central
nervous system neurons after transient cerebral ischemia and
in embryonic neurons when deprived of nerve growth factor,
implying a potentially important role for this protein in some
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of the neuronal cell deaths that occur during stroke or as a
result of neurotrophic factor deprivation (35, 60).
The mechanisms by which p21-Bax promotes apoptosis are
presently unclear. Like many other members of the Bcl-2 pro-
tein family, the Bax protein has a stretch of hydrophobic amino
acids located at its carboxyl terminus which presumably allows
the protein to posttranslationally insert into membranes.
Though the precise location of the p21-Bax protein in cells has
not been determined, immunohistostaining and immunofluo-
rescence studies indicate a mostly cytosolic location, in associ-
ation perhaps with organelles (14, 18, 24, 34, 36, 48, 84). All
Bcl-2 family proteins examined to date have been shown to
reside at least in part in mitochondrial membranes (14, 24, 36,
38, 48, 84). In the case of Bcl-2, the association with mitochon-
dria occurs via the outer rather than inner membrane, with the
protein oriented toward the cytosol (36, 38, 48).
In addition to a C-terminal transmembrane (TM) domain,
p21-Bax also contains three domains, BH1, BH2, and BH3,
which are well conserved among Bcl-2 family proteins. Recent
studies indicate that Bax homodimerizes with itself and het-
erodimerizes with Bcl-2 and other antiapoptotic Bcl-2 family
proteins in a BH3-dependent manner (18, 88). The functional
significance of these homo- and heterodimerization phenom-
ena has not been determined for Bax. With Bcl-2, however,
mutations in this antiapoptotic protein which impair its ability
to dimerize with Bax have been shown to abrogate its function,
implying that Bcl-2–Bax heterodimerization is important for
suppression of cell death (86).
Recently, it has been shown that when expressed in the
budding yeast Saccharomyces cerevisiae, the Bax protein con-
fers a lethal phenotype (17, 61, 62). Analogous to findings of
studies performed with mammalian cells, antiapoptotic mem-
bers of the Bcl-2 protein family, including Bcl-2, Bcl-XL, and
Mcl-1, are able to suppress the lethal function of Bax in yeast
cells, whereas the proapoptotic protein Bcl-XS and various
deletion mutants of Bcl-2 which are nonfunctional in mamma-
lian cells do not (4, 17, 19, 61). Interestingly, even some mu-
tants of Bcl-2 which retain the ability to bind Bax but which are
deficient in antiapoptotic activity in mammalian cells are also
unable to suppress Bax-mediated lethality in yeast cells (19).
Taken together, these observations suggest that at least some
aspects of Bax and Bcl-2 protein function may be conserved in
yeast cells, thus prompting us to compare some of the struc-
ture-function activities of the Bax protein in the unicellular
eukaryote S. cerevisiae with those in mammalian cells.
MATERIALS AND METHODS
Plasmids. A ;0.6-kbp murine bax cDNA subcloned into the EcoRI site of
pSKII (Stratagene, Inc.) (46) was liberated by EcoRI digestion, the ends were
blunted with Klenow fragment, and the fragment was subcloned by blunt-end
ligation into YEp51 at a blunted SalI site downstream of the GAL10 promoter.
Clones with the bax cDNA inserted in sense orientation were identified by
restriction digestion and confirmed by DNA sequencing.
The wild-type bax cDNA and various baxmutants were subcloned between the
EcoRI and XhoI sites in the two-hybrid plasmid pEG202 in frame with the
NH2-terminal LexA DNA binding domain sequences (13). The wild-type Bax
(encodes all 192 amino acids), Bax (DN) (mutant missing the first 58 amino
acids), Bax (DTM) (missing residues 172 to 192), and TM (contains only Bax
residues 172 to 192) were created by one-step PCRs using pSKII-bax as the
template and 59-GGGAATTCGCGGTGATGGACGGGT-39 [Bax and Bax
(DTM)], 59-GGGAATTCGCGGTGATGCTGAGCGAGTGTCTCCGGCGAA
TT-39 [Bax (DN)], or 59-GGAATTCGCGGTGATGACAGTGACCATCTTTG
TGGCTGG-39 (TM) as the forward primer and either 59-CTCTCGAGTCAG
CCCATCTTCTTCCAGATGGT-39 [Bax, Bax (DN), and TM] or 59-CTCTCG
AGTCACTGCCATGTGGGGGTCCCGAA-39 [Bax (DTM)] as the reverse
primer. The Bax mutant plasmids Bax (DIGDE), Bax (DBH1), and Bax (DBH2)
were prepared by the two-step PCR method of Ho et al. (22), using pSKII-bax as
the template and the following mutagenic primers in combination with the
wild-type Bax forward and reverse primers described above: Bax (DIGDE),
59-GAGTGTCTCCGGCGACTGGATAGCAATATGGAGCTG-39 (forward)
and 59-CATATTGCTATCCAGTCGCCGGAGACACTCGCTCAG-39 (re-
verse); Bax (DBH1), 59-GCAGCTGACATGTTTGCTCTCTTCTACTTTGCTA
GCAAACTGG-39 (forward) and 59-CTAGCAAAGTAGAAGAGAGCAAAC
ATGTCAGCTGCCACC-39 (reverse); and Bax (DBH2), 59-GTGAGCGGCTG
CTTGTCGGCCTCCTCTCCTACTTCGG-39 (forward) and 59-GAAGTAGG
AGAGGAGGCCGACAAGCAGCCGCTCACGGAG-39 (reverse). The Bax
(DIGDE) (DTM) plasmid was prepared as described above except substituting
the Bax (DTM) reverse primer for the wild-type Bax reverse primer. This cDNA
was subcloned from pEG202 into pJG4-5 by digestion with EcoRI and XhoI.
To create the chimeric plasmid pEG202-Bax/Mas70, a cDNA encoding Bax
residues 1 to 171 was generated by using pSKII-bax template DNA and the wild-
type Bax forward primer described above with 59-GGTTGCCAAAATGGCCT
GCCATGTGGGGGTCCCGAA-39 as the reverse primer. In addition, a cDNA
encoding the Mas70p TM domain (residues 11 to 29) was generated by using
plasmid YEplac181-Mas70 (20) as a template and 59-GACCCCCACATGGCA
GGCCATTTTGGCAACCGTTGCTG-39 and 59-CTCTCGAGTCACTTCTTG
TAATAATAGTAGGCACCGATGG-39 as the forward and reverse primers,
respectively. These two gel-purified PCR products then combined in a final PCR
using wild-type Bax forward primer and the Mas70p TM reverse primer. Plas-
mids pEG202-Fas, pEG202-lamin, pJG4-5-Ha-Ras, pJG4-5-Bcl-2 (DTM), and
pJG4-5-lamin have been described previously (19, 61, 63).
Plasmid pHA-Shin contains three tandem copies of a hemagglutinin (HA) tag
with an accompanying start codon and Kozak consensus sequence for translation
in pcDNA-3 (Invitrogen, Inc.), subcloned downstream of the cytomegalovirus
promoter between the HindIII and NcoI sites. The bax sequences in pEG202-
Bax, pEG202-Bax (DTM), and pEG202-Bax (DIGDE) were excised by digestion
with EcoRI and XhoI and subcloned in frame with the HA tag-encoding se-
quences in EcoRI-XhoI-digested pHA-Shin. The Bax (DTM) cDNA was also
subcloned into the green fluorescent protein (GFP) plasmid pS65T (Clontech,
Inc.) between the BglII and EcoRI sites. The proper construction of all plasmids
was confirmed by DNA sequencing.
Yeast cell culture and transformations. All strains were maintained on mini-
mal medium (MM) supplemented with essential amino acids (MM-A) and ad-
ditional amino acids as required for maintenance of plasmid selectable markers.
The following strains were used for analysis of Bax effects on cytotoxicity: EGY48
(MATa trp1 ura3 his3 leu2::plexAop6-leu2), EGY191 (MATa trp1 ura3 his3
leu2::plexAop1-leu2), MYY291 (MATa his3 ura3 leu2), L40 (MATa trp1 leu2 his3
ade2 LYS2::lexAop4-HIS3 URA3::lexAop8-lacZ), and BF264-15Dau (MATa ade1
his2 leu2 trp1 ura3). Transformations were performed by the lithium acetate
method, using 1.5 mg of plasmid DNA and 5 mg of sheared, denatured salmon
sperm (carrier) DNA. For transformations with YEp51 and pEG202-based plas-
mids, cells were plated on leucine-deficient and histidine-deficient MM-A, re-
spectively.
For experiments with cells containing YEp51 or YEp51-Bax, a single colony of
transformed cells growing on leucine-deficient MM-A supplemented with 2%
(wt/vol) glucose was grown in 10 ml of medium with vigorous aeration at 308C to
an optical density at 600 nm (OD600) of ;0.8 to 1.0. Cells were pelleted by
centrifugation (1,000 3 g) for 10 min and resuspended in 10 ml of leucine-
deficient MM-A with either 2% glucose or 2% galactose–1% raffinose. After
culturing for various times (0 to 4 days), an aliquot of cells was removed for
trypan blue dye exclusion assay, counting ;400 total (live and dead) cells.
Alternatively, the cell density of cultures was determined by counting unstained
cells, and 103 cells were spread on either glucose- or galactose-containing
leucine-deficient MM-A plates. Plates were cultured at 308C for 4 days, and the
number of colonies was counted.
Two-hybrid assays. Protein-protein interactions were evaluated by yeast two-
hybrid assay essentially as described in detail previously, using either EGY48
cells for LEU2 reporter gene assays or EGY191 cells for lacZ reporter gene
assays, in conjunction with plasmids pEG202 (LexA DNA binding domain) and
pJG4-5 (B42 transactivation [TA] domain) (13, 19, 61). Growth on leucine-
deficient plates was scored 4 days after spotting cells on MM plates containing
2% galactose–1% raffinose to induce expression of the TA domain-containing
proteins from the GAL1 promoter in pJG4-5. Cells spotted on MM-glucose
plates served as negative controls. Filter assays were similarly performed for
b-galactosidase measurements, using cells plated on either galactose- or glucose-
containing MM supplemented with 20 mg of leucine per ml. Colorimetric results
were photographed after 0.5 to 2 h.
Immunoblot assays. Yeast cells were grown to an OD600 of;1 to 2. Cells were
then collected by centrifugation and washed with phosphate-buffered saline
(PBS). The washed cell pellets were resuspended in ;3 volumes of ice-cold lysis
buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% Nonidet P-40 [NP-40], 0.1
sodium dodecyl sulfate [SDS], 0.5% sodium deoxycholate, protease inhibitors
[57]) in Eppendorf microcentrifuge tubes. An equal volume of acid-washed,
chilled glass beads (0.5-mm diameter) (Sigma, Inc.) was added, and the tubes
were vortexed vigorously for 2 min. The beads were pelleted at 16,000 3 g for 10
min at 48C, and the supernatant was transferred to a fresh tube. Samples were
normalized for protein content by the bicinchoninic acid method (Pierce, Inc.),
and 15 to 30 mg was loaded per lane into SDS–12% polyacrylamide gels. After
transfer to nitrocellulose membranes, blots were preblocked and antigen detec-
tion was performed as described previously, using 0.1% (vol/vol) anti-LexA or
anti-Bax rabbit antiserum (34, 71) followed by horseradish peroxidase-conju-
gated goat anti-rabbit immunoglobulin G (IgG). Antibody detection was accom-
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plished by an enhanced chemiluminescence method (Amersham, Inc.) with ex-
posure to X-ray film (XAR; Kodak, Inc.).
Immunofluorescence. Indirect immunofluorescence was performed as de-
scribed previously (42, 43). Briefly, yeast cells were fixed by addition of formal-
dehyde to 4% (wt/vol) and shaken gently for 30 min at room temperature. Cells
were collected by centrifugation, resuspended in 1/10 volume of buffer A (50 mM
phosphate buffer, 35 mM KH2PO4, 15 mM K2HPO4, 0.5 mM MgCl2 [pH 6.5])
containing 4% formaldehyde and shaken for an additional 30 min. Cells were
then washed three times with buffer A containing 1.2 M sorbitol, and cell wall
material was removed by incubation at room temperature in buffer A containing
1.2 M sorbitol, 27.5 mM b-mercaptoethanol, and 0.1 mg of Zymolyase 20T per
ml. Cells were then washed twice with PBS containing 2 mg of bovine serum
albumin (BSA) per ml (PBS-BSA) at room temperature and three times for 5
min each at 2208C with 0.1 ml of acetone. Ten to twenty microliters of the final
acetone cell suspension was then spotted onto polylysine-coated slides. Slides
were blocked by incubation in fresh PBS-BSA for 1 h with three buffer changes.
PBS-BSA was replaced with 10 ml of primary antibody mix (0.073 mg of rat IgM
monoclonal anti-Bax [Pharmingen, Inc.] per ml) and a 1:100 dilution of mouse
IgG monoclonal anti-OM14 ascites fluid (42, 60) in PBS-BSA for 2 h. Each well
was washed eight times with PBS-BSA, and 10 ml of secondary antibody solution
(rhodamine isothiocyanate-goat anti-rat [IgM] and fluorescein isothiocyanate-
donkey anti-mouse [IgG, heavy and light chains] from Jackson Laboratories,
each at 30 mg/ml in PBS-BSA) was added for 1 h. After another eight washes, 10
ml of a 1-mg/ml solution of 49,6-diamidino-2-phenylindole (DAPI) in PBS-BSA
was added for 10 min. Wells were again washed eight times with PBS-BSA and
allowed to air dry. All antibody and DAPI incubations were performed in a dark,
humidified chamber. After mounting in a solution containing 1 mg of p-phenyl-
enediamine per ml, 0.13 PBS, and 90% (vol/vol) glycerol, slides were viewed
under fluorescence. Images were viewed under a 1003 oil immersion objective,
captured by a charge-coupled device camera after a further 53 magnification,
and printed on Sony thermal imaging film.
Mammalian cell transfection and apoptosis assay. Rat-1 cells were main-
tained between 10 to 90% in Dulbecco modified Eagle medium (DMEM) with
10% fetal calf serum, 1 mM L-glutamine, and antibiotics. Cells at 50% confluence
in 24-well plates were transfected with 0.25 mg of pCMV-b-gal and 0.6 mg of
plasmid pHA-Shin, pHA-Bax, pHA-Bax (DTM), or pHA-Bax (DIGDE) mixed
with 5 mg of Lipofectamine (GIBCO/BRL, Inc.). After 24 h, cell monolayers
were washed twice with PBS, and the adherent cells were fixed in 2% parafor-
maldehyde–0.1% glutaraldehyde in PBS. b-Galactosidase activity was detected
by using 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) as a sub-
strate as described previously (37). The number of blue cells was counted by
microscopic examination.
293 cells (;5 3 105) were cultured in 60-mm-diameter dishes in 3 ml of
DMEM containing 10% horse serum (Donor Equine Serum, Tulare, Calif.) for
12 to 20 h. The cells were then transfected with 7 mg of pcDNA3-HA-Bax,
pcDNA3-HA-Bax (DTM), pcDNA3-HA-Bax (DIGDE), or parental pcDNA3-
HA plasmid DNA by a calcium phosphate precipitation method. Seven hours
later, the transfection medium was replaced with fresh prewarmed (378C)
DMEM, and the cells were cultured for another 28 h. Floating cells in culture
supernatant were recovered by centrifugation of the culture medium at 400 3 g
for 10 min. The adherent cells were recovered by trypsinization, pooled with
floating cells, and washed once with the medium before fixation in 3.7% para-
formaldehyde–PBS for 10 min. After one wash with PBS (pH 7.4), cells were
resuspended in 1 ml of PBS containing 1 mg of DAPI, incubated for 10 min at
room temperature, and washed three times with PBS. The percentage of cells
with fragmented nuclei was determined by viewing with a fluorescence micro-
scope.
Coimmunoprecipitation experiments. 293 cells (2 3 106) were cultured in 10
ml of DMEM containing 10% horse serum overnight. The cells were then
transfected with 20 mg of each of pcDNA3-HA-Bax, pcDNA3-HA-Bax (DTM),
pcDNA3-HA-Bax (DIGDE), or parental pcDNA3-HA vector by a calcium phos-
phate precipitation method. Approximately 60 h later, the cells were lysed in 0.3
ml of NP-40 lysis buffer (10 mMN-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid [HEPES; pH 7.5], 142.5 mM KCl, 5 mMMgCl2, 1 mM EGTA, 0.2% NP-40)
containing 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 mg/ml) and apro-
tinin (5 mg/ml). Immunoprecipitations were performed by incubation with 20 ml
of protein G-Sepharose beads preabsorbed with 4 mg of anti-HA mouse mono-
clonal antibody (12CA5; Boehringer Mannheim) at 48C for 3 h. After three
washes in 1.5 ml of NP-40 lysis buffer, immune complexes were subjected to
SDS-polyacrylamide gel (14%) electrophoresis (PAGE)–immunoblot analysis
using anti-HA or anti-human Bax antiserum (33). Antibody detection was ac-
complished by use of an enhanced chemiluminescence system (Amersham) with
biotinylated secondary antibodies and horseradish peroxidase-avidin.
Localization of Bax protein in 293 cells by using GFP. 293 cells (23 106) were
transiently transfected with 20 mg of pS65-Bax (DTM) or parental pS65T plasmid
DNA by a calcium phosphate precipitation method as described above. Approx-
imately 60 h later, the cells were collected and seeded in wells of 24-well plates
containing coverslips pretreated with fibronectin for overnight incubation at
378C. The medium was removed from the wells, and fresh prewarmed (378C)
medium containing 5 to 25 nMMitoTracker (Molecular Probes, Inc.) was added.
After incubation for 30 min at 378C in 95%-5% air-CO2, the cells were then
washed once with PBS (pH 7.3) and fixed in 3.7% paraformaldehyde for 15 min
at room temperature. The cells were then rinsed in PBS three times before
mounting in Vectashield mounting medium (Vector Laboratories, Inc.) for con-
focal analysis and photography using an Axiophot photomicroscope (Zeiss, Inc.,
Oberkochen, Germany).
Electron microscopy (EM). Yeast cells containing plasmid YEp51-Bax were
cultured for 1 to 2 days in glucose- or galactose-containing medium, washed once
with PBS, and then fixed for 30 min in 4 M phosphate buffer containing 3%
glutaraldehyde. After being washed twice in 4 M phosphate buffer, cells were
embedded in Epon and then postfixed and counterstained in 0.5% osmium
tetroxide in 1% uranyl acetate. Ultrathin sections were mounted on grids and
imaged with a Hitachi H-600 electron microscope.
RESULTS
Conditional expression of Bax in yeast cells confers a lethal
phenotype but does not induce oligonucleosomal DNA degra-
dation. A cDNA encoding the full-length mouse Bax protein
was subcloned into the episomal plasmid YEp51, thus placing
Bax under the control of a GAL10 promoter and allowing for
conditional expression of this protein when cells are grown in
galactose-containing medium. Figure 1A shows an immuno-
blot analysis of the Bax protein in yeast cells that had been
transformed with plasmid YEp51-Bax. Comparisons were made
with cells transformed with plasmid YEp51 lacking an insert, as
a negative control. When transferred from glucose-based me-
dium, in which the GAL10 promoter is repressed, to galactose-
based medium, the expected 21-kDa Bax protein accumulated
to easily detectable levels within 12 h in the cells containing
plasmid YEp51-Bax but not in cells harboring the YEp51 con-
trol plasmid. The levels of Bax protein produced in yeast cells
were comparable to those seen in some mammalian cell lines,
when normalized for total protein content (not shown).
Consistent with the galactose-inducible nature of Bax pro-
tein production in these cells, plating the YEp51-Bax transfor-
mants on semisolid medium that contained galactose resulted
in essentially complete inhibition of colony formation, whereas
colony formation on glucose-based medium occurred with ap-
proximately the same efficiency as observed for control trans-
formants containing plasmid YEp51 without the bax cDNA
(Fig. 1B). Cotransformation of YEp51-Bax-containing yeast
cells with a Bcl-2 expression plasmid, pEG202-Bcl-2 (DTM),
restored colony formation to about half of control levels (not
shown).
To further characterize the effects of Bax on yeast cells,
YEp51-Bax- and YEp51-transformed cells were grown in glu-
cose-based medium and then switched to fresh medium con-
taining either galactose or glucose. After various times, cells
were recovered from liquid cultures by centrifugation and cell
viability was determined on the basis of the ability to exclude
trypan blue dye. Figure 1C presents results from a represen-
tative experiment, showing a time-dependent decline in the
percentage trypan blue-excluding cells in cultures of YEp51-
Bax transformants when cultured in galactose-containing me-
dium. The appearance of cells that failed to exclude trypan
blue was evident within 12 h after placing cells into galactose-
containing medium and generally reached maximal levels at
2 to 3 days. By phase-contrast light microscopy, the dye-ex-
cluding and -nonexcluding cells did not appear to be morpho-
logically different in terms of overall size or budding (data
not shown). When stripped of their cell wall with Zymolyase,
the trypan blue-positive cells essentially disintegrated whereas
the dye-excluding cells formed spheroplasts. In contrast to the
accumulation of cells which took up trypan blue dye in cultures
of YEp51-Bax transformants in galactose-containing medium,
cells grown in glucose-based medium remained mostly dye
negative (Fig. 1C). The specificity of these results was further
confirmed by examination of YEp51 control transformants,
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which remained mostly viable regardless of whether cultured in
glucose- or galactose-based medium.
To further examine the kinetics of Bax-induced death of
yeast cells, YEp51-Bax transformants were cultured for various
times in galactose-containing medium to induce Bax expres-
sion and then washed and plated on glucose-based semisolid
medium in an effort to rescue residual viable cells. Numbers of
rescuable colonies were markedly reduced within 1 day of
placing these cells into galactose-containing medium, and by 2
to 3 days, very few viable, colony-forming cells remained in
cultures (Fig. 1D). In contrast, growth of YEp51 control trans-
formants in galactose-containing medium had no adverse ef-
fect on the frequency of viable colony-forming cells. Thus,
conditional expression of Bax resulted in an irreversible inhi-
bition of colony formation, consistent with a lethal phenotype.
Furthermore, the ability to rescue residual viable cells was
dependent on the length of time of Bax induction, with essen-
tially no or very few cells surviving after 2 days. These data
therefore provide further confirmation that Bax confers a le-
thal phenotype in S. cerevisiae, as opposed to merely inhibiting
cell cycle. In addition, DNA content analysis by flow cytometric
analysis of propidium iodide-stained fixed cells failed to reveal
accumulation of Bax-expressing cells in any particular phase of
the cell cycle (data not shown).
In mammalian cells, apoptotic cell death is characterized by
nuclear fragmentation and chromatin condensation, often (but
not always) with accompanying cleavage of genomic DNA into
fragments representing integer multiples of the internucleoso-
mal distance (;200 bp) (54, 74, 83). Staining Bax-expressing
yeast cells with the DNA-binding fluorochrome DAPI failed to
reveal evidence of nuclear fragmentation, although loss of nu-
clear staining occurred at later times after induction of Bax
(data not shown). In addition, agarose gel electrophoresis anal-
ysis of yeast chromosomal DNA did not reveal the oligonu-
cleosomal pattern of DNA bands typical of apoptotic cells (Fig.
1E). Rather, a diffuse smear of DNA fragments was evident
when DNA was prepared from YEp51-Bax transformants after
2 days of culture in galactose-containing medium. At earlier
times analyzed after placement of YEp51-Bax cells into galac-
tose medium (12 and 24 h), essentially no difference from
control YEp51 transformants was detected in the mobility of
FIG. 1. Conditional expression of Bax confers a lethal phenotype in yeast
cells but does not induce oligonucleosomal DNA fragmentation. (A) Strain
EGY191 yeast cells were transformed with YEp51 (control; lanes C) or YEp51-
Bax (lanes B) plasmids, grown in glucose-based medium at an OD600 of ;1.0,
then switched to galactose-based medium, and cultured at 308C for 0, 6, or 12 h.
Protein lysates were prepared, and 30-mg aliquots were subjected to SDS-
PAGE–immunoblot assay using an anti-Bax antiserum (34). The band shown
represents mouse p21-Bax. (B) EGY191 cells transformed with either YEp51
(control) or YEp51-Bax plasmid DNA were spread on either glucose- or galac-
tose-containing plates. Photographs were taken after culturing at 308C for 4 days.
(C) EGY191 cells containing either YEp51 (open symbols) or YEp51-Bax
(closed symbols) were grown in glucose-based medium to an OD600 of;1.0, then
washed three times, and cultured for 0 to 4 days in either fresh glucose-based
(circles) or galactose-based (triangles) medium. Aliquots of cell cultures were
removed, and the percentage of cells excluding trypan blue dye was determined
by counting a total of ;400 cells. Data are representative of two experiments.
(D) Same as panel C except that 103 total cells were plated on glucose-based
medium. The number of colonies which formed within 4 days of culture at 308C
is indicated for cells containing plasmid YEp51 (open circles) or YEp51-Bax
(closed circles). Data are representative of four experiments. (E) Cells contain-
ing either YEp51 (lanes C) or YEp51-Bax (lanes B) were cultured for 0, 12, 24,
or 48 h in galactose-based medium, and DNA was isolated from 107 Zymolyase-
prepared spheroplasts. DNA samples were size fractionated by electrophoresis in
2% agarose gels and stained with ethidium bromide. As a control for oligonu-
cleosomal DNA fragmentation, DNA derived from 106 Jurkat T cells which had
been cultured for 4 h with 20 ng of anti-Fas antibody CH11 (Pharmingen, Inc.)
per ml was included in the same gel (lane J).
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chromosomal DNA by conventional agarose gel electrophore-
sis, despite the fact that typically about half of the Bax-express-
ing cells had lost viability within 24 h after being switched to
galactose medium (Fig. 1C and D). In contrast, treating the
human T-cell line Jurkat with anti-Fas antibody (a well-known
apoptotic stimulus for these cells [71]) for 4 h resulted in DNA
degradation in the typical oligonucleosomal pattern (Fig. 1E).
Thus, the DNA degradation seen in the setting of Bax-induced
death in yeast cells occurs as a relatively late event, probably
after loss of plasma membrane integrity, and does not appar-
ently involve endonuclease mechanisms that are the same as or
similar to those commonly utilized by many mammalian cells
during apoptotic cell death.
To further characterize the cell death process induced by
Bax in yeast cells, we undertook EM analysis of cells containing
YEp51-Bax after 1 to 2 days of growth in either glucose- or
galactose-containing medium. EM analysis of yeast cells grow-
ing in glucose-containing medium, in which Bax expression is
not induced, showed typical morphology for normal S. cerevi-
siae, with a central vacuole, several mitochondria, and homo-
geneous nuclear chromatin except for the nucleolar region
(Fig. 2A). In contrast, cells grown in galactose-containing me-
dium developed a variety of morphological abnormalities,
which presumably reflected a continuum of severity. For ex-
ample, some cells were largely normal but contained increased
numbers of cytosolic vacuoles (Fig. 2B). Cells further into the
degenerative process were characterized by dissolution of the
nucleus, enlargement of cytoplasmic vacuoles, and evidence of
mitochondrial swelling (Fig. 2C). Finally, cells in the terminal
stages of the cell death process had undergone nearly complete
autophagy, with absence of the nucleus and most cytosolic
organelles, and contained only the remnants of what appeared
to be ruptured mitochondria. The cell wall was evidently intact
and abutted by electron-dense material that appeared to be
largely contained within membranous structures. Taken to-
gether, therefore, the data presented in Fig. 1 and 2 indicate
that the cell death induced by Bax in yeast cells does not occur
by mechanisms consistent with apoptosis, as currently recog-
nized in mammalian and metazoan species.
Membrane targeting of Bax protein is required for its lethal
phenotype in yeast cells. Like most members of the Bcl-2
protein family, the Bax protein contains a stretch of hydropho-
bic amino acids near its C terminus that meets computer pre-
dictions for a TM domain (55). To determine the role of this
membrane anchoring sequence for the function of the Bax
protein in yeast cells, we prepared expression plasmids that
contained cDNAs encoding either the full-length Bax protein
or a truncation mutant of Bax lacking the C-terminal TM
domain [Bax (DTM)] under the control of a constitutive ADH
promoter (Fig. 3A, top). These and all other Bax mutant pro-
teins subsequently described in this report were expressed as
fusion proteins which contained an N-terminal LexA DNA
binding domain lacking a nuclear localization signal sequence,
similar to the approach used in previous studies (4, 19, 61). The
LexA sequences served as an epitope tag for monitoring ex-
pression of proteins and also were intended to promote the
stability of truncated proteins when expressed in S. cerevisiae
(see below).
Plasmids encoding the full-length Bax or Bax (DTM) protein
and carrying a HIS3 marker were then transformed into yeast
cells, and the cells were cultured on histidine-deficient me-
dium. Four days later, the relative numbers of colonies of
viable cells were enumerated, and the data were normalized
relative to transformations performed with either the same
parental plasmid pEG202 encoding the LexA domain alone or
a LexA-lamin fusion protein which served as a negative con-
trol. As shown in Fig. 3A, the full-length Bax plasmid sup-
pressed colony formation by .99% in this assay. In contrast,
the Bax (DTM) plasmid had no inhibitory effect. The inhibition
of colony formation by the full-length Bax expression plasmid
did not appear to be due to nonspecific toxicity caused by the
bax cDNA sequences, because essentially no suppression of
colony formation occurred when cells were transformed with
the same plasmid in which the bax cDNA has been subcloned
in reversed (antisense) orientation (Fig. 3A). Moreover, co-
transfection of plasmid pJG4-5-Bcl-2 (DTM), which produces a
Bcl-2 fusion protein, restored colony formation to ;50% of
control levels (not shown), as reported previously (61).
This experiment suggested that the TM domain of Bax is
required for its lethal phenotype in yeast cells. However, it was
also possible that the TM domain was nonspecifically toxic
when overexpressed in yeast cells, perhaps by indiscriminately
impairing the function of other membrane proteins. To explore
this possibility, an expression plasmid that encoded a N-LexA
fusion protein containing only the TM domain of Bax was
prepared. When expressed in yeast cells, this LexA-TM fusion
protein had no inhibitory effect on colony formation, suggest-
ing that the TM domain of Bax is not nonspecifically toxic (Fig.
3A).
Since these data suggested that membrane targeting is crit-
ical for the lethal phenotype of Bax in yeast cells, we next
attempted to restore cytotoxic function to the Bax (DTM)
protein by fusing this portion of Bax (amino acids 1 to 171)
with a heterologous TM domain derived from another protein.
The TM domain of the yeast outer-membrane mitochondrial
protein Mas70p was chosen for these experiments on the basis
of previous reports showing that this sequence can restore
optimal function to C-truncation mutants of Bcl-2 that lack a
TM domain (52) and because of evidence that most Bcl-2
family proteins are primarily associated with mitochondria (14,
24, 36, 38, 48, 84). When transformed into yeast cells, expres-
sion plasmids encoding the Bax-Mas70p fusion protein sup-
pressed colony formation with efficiencies comparable to that
of the wild-type Bax protein (Fig. 3A).
Immunoblot assays were performed to verify that the various
expression plasmids described above produced the expected
fusion proteins. However, because no viable colonies of cells
could be recovered from cells transformed with plasmids en-
coding the full-length Bax and Bax-Mas70p proteins, it was
necessary to cotransform cells with a Bcl-2 expression plasmid.
For these immunoblot experiments, we took advantage of the
N-terminal LexA tag sequences for detection of proteins by
using an anti-LexA antiserum (gift of E. Golemis, Fox Chase
Cancer Center, Philadelphia, Pa.). All yeast cell lysates were
normalized for total protein content prior to analysis. As
shown in Fig. 2B, the Bax (DTM) protein was produced at
levels about three times higher than those of the full-length
Bax protein, thus excluding insufficient production of this C-
truncation mutant as an explanation for its failure to suppress
colony formation. Similarly, the LexA-TM fusion protein was
produced at levels about five times higher than those of the
wild-type Bax protein, indicating that the inability of the TM
domain of Bax by itself to kill yeast cells was not an artifact of
poor levels of expression. The Bax-Mas70p fusion protein was
produced at levels comparable to those of the wild-type Bax
protein (Fig. 3B).
Bax is targeted to mitochondria in yeast cells. Because
membrane anchoring was critical for the lethal phenotype of
Bax in yeast cells, we compared the intracellular locations of
the Bax, Bax (DTM), and Bax-Mas70p proteins by immunoflu-
orescence microscopy, using a mouse monoclonal anti-Bax an-
tibody in conjunction with a rhodamine-labeled secondary an-
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tibody. As shown in Fig. 4, the Bax and Bax-Mas70p proteins
were located in the cytosol of yeast cells in a punctate immu-
nofluorescence pattern, suggestive of organellar association.
Costaining of these cells with a rabbit antiserum specific for the
yeast mitochondrial outer-membrane protein OM14 (using a
fluorescein isothiocyanate-labeled secondary antibody) indi-
cated that these organelles with which Bax was associated were
probably mitochondria. Consistent with this idea, when these
same cells were incubated with the DNA-binding fluoro-
chrome DAPI, which labels both chromosomal and mitochon-
drial DNA, the Bax immunofluorescence colocalized with the
mitochondrial DNA staining but not nuclear genomic DNA
staining (Fig. 4). In contrast to the wild-type Bax and Bax-
Mas70p proteins, the immunofluorescence pattern obtained
for the Bax (DTM) protein revealed mostly diffuse cytosolic
and nuclear staining which lacked any obvious colocalization
FIG. 2. EM analysis of Bax-mediated cell death in yeast cells. EGY48 cells containing YEp51-Bax were cultured in glucose-containing (A) or galactose-containing
(B to D) medium for 1 to 2 days. Cell morphology was then analyzed by EM (magnification, 3;45,000). The cells shown in panels B to D are representative of the
spectrum of changes that were seen in cells expressing Bax, from least to most affected.
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with OM14 or DAPI. Taken together, these data strongly sug-
gest that the Bax protein is associated with mitochondria when
expressed in yeast cells, whereas the Bax (DTM) protein, which
lacks cytotoxic function, fails to associate with these organelles.
A well-conserved four-amino-acid sequence in the BH3 do-
main of Bax is required for homodimerization. Recently we
demonstrated that the BH3 domain of Bax is absolutely re-
quired for homodimerization with Bax and for heterodimer-
ization with Bcl-2, on the basis of the results of yeast two-
hybrid assays and in vitro protein interaction assays (88).
Though binding constants (Kd) have not been determined to
date, Bax-Bax homodimerization appears to occur in the com-
plete absence of the BH1, BH2, and N-terminal (residues 1 to
58) domains with efficiencies comparable to that of the full-
length Bax protein (88). Within the BH3 domain of Bax and its
proapoptotic homologs Bak and Bik is a conserved four-ami-
no-acid sequence, IGDE (residues 66 to 69 in the mouse Bax
protein). We therefore prepared two-hybrid expression plas-
mids encoding a deletion mutant of Bax lacking these four
amino acids, Bax (DIGDE), fused with either an N-terminal
LexA DNA binding domain or a B42 TA domain and then
compared the wild-type Bax and Bax (DIGDE) proteins with
regard to ability to homodimerize, using lacZ and LEU2 re-
porter genes under the control of lexA operators (13). Both the
Bax and Bax (DIGDE) proteins were expressed without their
TM domains to prevent problems with nuclear targeting of the
hybrid proteins and to avoid Bax-mediated cytotoxicity. Immu-
noblotting demonstrated comparable levels of expression of
the wild-type and DIGDE Bax proteins (not shown).
With either b-galactosidase filter assays (Fig. 5) or growth
on leucine-deficient media (not shown) as endpoints, the wild-
type Bax protein formed strong two-hybrid interactions with
itself when cells were plated on galactose-based medium,
which induces expression of the TA domain-containing partner
protein in these assays (under control of GAL1 promoter), but
not when plated on glucose-based medium. In contrast, the
Bax (DIGDE) protein failed to interact with itself at levels
substantially above background, as defined by comparisons
with two-hybrid results of assays in which Bax (DIGDE) was
paired with either R-Ras or Fas (cytosolic domain) as a neg-
ative control (Fig. 5). The Bax (DIGDE) protein also failed to
interact with Bcl-2 in two-hybrid assays, whereas the wild-type
Bax protein formed strong interactions with Bcl-2 (Fig. 5).
Bax homodimerization is required for lethal phenotype in
yeast cells. To compare the functions of the wild-type and
DIGDE mutants of Bax in yeast cells, we prepared expression
plasmids containing a HIS3 marker that encoded the Bax and
Bax (DIGDE) proteins with TM domains under the control of
an ADH promoter. When transformed into yeast cells and
plated on histidine-deficient medium, the full-length, wild-type
Bax protein suppressed colony formation by .99% (Fig. 6A).
In contrast, the Bax (DIGDE) protein was completely inactive
in this assay, allowing for colony formation at frequencies
comparable to those of negative control plasmids. Immunoblot
analysis demonstrated that the Bax (DIGDE) protein was pro-
duced at levels;3-fold higher than those of wild-type Bax (Fig.
6B), excluding poor levels of expression of this mutant protein
as a trivial explanation for the lack of function in yeast cells.
These results therefore suggest that for Bax to manifest its
lethal phenotype in yeast cells, it must be able to homodimer-
ize. The findings also provide further evidence that the cyto-
toxic effects of Bax in yeast cells cannot be attributed to a
nonspecific mechanism, since deletion of just four amino acids
completely abolished the activity of this protein.
Though homodimerization of Bax appeared to be important
for its function in yeast cells, we wished to explore whether
mutants of Bax that lacked other conserved domains but which
remained capable of homodimerizing also retained their lethal
function when expressed in yeast cells. For this purpose, Bax
(DBH1), Bax (DBH2), and Bax (DN) mutant proteins (with
their TM domains) were tested for suppression of colony for-
mation in transformation assays as described above. As shown
in Fig. 6A, the Bax (DBH1), Bax (DBH2), and Bax (DN)
proteins retained ;50, ;60, and ;80%, respectively, of their
death-promoting function in yeast cells. Immunoblot analysis
confirmed that all of these proteins were expressed at levels at
FIG. 3. Targeting to intracellular membranes is essential for the lethal phe-
notype of Bax in yeast cells. (A) Bax, Bax (DTM), TM, and Bax-Mas70p were
expressed as fusion proteins containing an NH2-terminal LexA domain under the
control of an ADH promoter in plasmid pEG202, which contains a HIS3 gene.
After transformation into yeast cells and plating on histidine-deficient media for
4 days at 308C, the colonies were counted on the plates. The data shown were
obtained from three independent experiments performed on different days with
different preparations of plasmid DNA (mean 6 standard deviation) and are
expressed as percentages relative to cells transformed with either pEG202 lack-
ing a cDNA insert or pEG202-lamin, which were used as negative controls and
whose level was arbitrarily set at 100%. (B) The relative levels of the LexA fusion
proteins Bax, Bax (DTM), TM, and Bax-Mas70p described above were examined
by immunoblot analysis of 20 mg of total protein lysate, using an anti-LexA
antibody. All cells had been cotransformed with plasmid pJG4-5-Bcl-2 (DTM) to
suppress the lethal effects of full-length Bax and Bax-Mas70p.
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least equal to or (in most cases) greater than that of the
wild-type Bax protein (Fig. 6B). Thus, while these other do-
mains within the Bax protein may contribute to the optimal
function of this protein, none is absolutely required for Bax-
mediated killing of yeast cells.
The Bax (DIGDE) protein is defective in promoting apopto-
sis in mammalian cells. Because versions of Bax that lacked a
TM domain or that were incapable of homodimerizing repre-
sented loss-of-function mutants in yeast cells, we contrasted
the bioactivities of these proteins with that of the wild-type Bax
protein in mammalian cells. For these experiments, we con-
structed expression plasmids that encoded the Bax, Bax
(DTM), and Bax (DIGDE) proteins with NH2-terminal HA
epitope tags under the control of a strong constitutive viral
promoter (cytomegalovirus immediate-early region). These plas-
mids or the empty vector (control) were cotransfected with the
b-galactosidase-producing plasmid pCMV-b-Gal into Rat-1 fi-
broblasts, and 2 days later the relative numbers of b-galacto-
sidase-expressing (blue) cells were enumerated. In this assay,
Rat-1 cells which die by apoptosis round up and detach from
dishes, making the relative number of adherent blue cells a
good indicator of Bax protein function. This same transient
transfection assay has been used previously for studies of Bak,
Bik, and other Bcl-2 family proteins, as well for studies of
several types of proapoptotic proteins (6, 8, 9, 45, 78).
As shown in Fig. 7A, very few blue cells were detected in
monolayer cultures of Rat-1 cells when transfected with the
wild-type Bax expression plasmid, and about half of these b-ga-
lactosidase-positive cells had obvious morphological features
of apoptosis, such as rounded shape and shrunken size as well
as nuclear fragmentation, which was confirmed by propidium
iodide staining (not shown). Bax (DTM) was only slightly less
effective than wild-type Bax in this assay (Fig. 7A). Thus, while
the presence of a membrane-anchoring domain is crucial for
the prodeath function of Bax in yeast cells, it is not required for
function in mammalian cells. In contrast, in cultures of Rat-1
cells transfected with the Bax (DIGDE) plasmid, blue cells
were present at levels comparable to or slightly higher than
those of control plasmid-transfected cells, and ,10% of these
had morphological features suggestive of apoptosis. Similar to
the loss of function seen in yeast cells, therefore, this ho-
FIG. 4. Mitochondrial localization of Bax detected by indirect immunofluorescence. Bax, Bax (DTM), and Bax-Mas70p were expressed as LexA fusion proteins in
yeast cells. The cells were also cotransformed with the expression plasmid pJG4-5-Bcl-2 (DTM) to maintain cell survival. The primary antibodies used were rat IgM
monoclonal anti-Bax and mouse IgG monoclonal anti-OM14. The secondary antibodies were rhodamine isothiocyanate-goat anti-rat IgM and fluorescein isothiocya-
nate-donkey anti-mouse IgG, respectively. The cells were also stained with DAPI (see Materials and Methods for details). The right-most panel shows phase-contrast
photomicrographs of the same cells.
FIG. 5. Two-hybrid comparison of dimerization by Bax and Bax (DIGDE).
Bax, Bax (DIGDE), Bcl-2, and other proteins tested in this experiment were
expressed in EGY191 as fusion proteins with either NH2-terminal LexA DNA
binding domain from pEG202 or TA domain from plasmid pJG4-5, as indicated.
The data shown were obtained from b-galactosidase filter assays. Three inde-
pendent transformants were plated on either galactose- or glucose-containing
medium.
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modimerization-defective mutant of Bax failed to promote ap-
optosis in mammalian cells.
Similar results were obtained in 293 kidney epithelial cells.
Because the efficiency of transfection was much higher for
these cells (;80%) than for Rat-1 cells, 293 cells were exam-
ined directly by DAPI staining without b-galactosidase as a
marker plasmid. Approximately one-quarter of the 293 cells in
cultures transfected with either the Bax or Bax (DTM) expres-
sion plasmid developed the nuclear fragmentation typical of
apoptosis, compared with ,5% of the cells transfected with
the Neo control or Bax (DIGDE)-producing plasmids (Fig. 7B
and C).
To confirm that the Bax (DIGDE) protein was stable when
produced in mammalian cells, 293 human kidney epithelial
cells were transiently transfected with the same Bax and Bax
(DIGDE) expression plasmids used for the Rat-1 transfection
assay. Immunoblot analysis performed with a monoclonal an-
tibody directed against the HA epitope tags demonstrated
comparable levels of the HA-Bax and HA-Bax (DIGDE) pro-
teins, suggesting that the failure of the Bax (DIGDE) protein
to promote cell death was not attributable to protein instability
(Fig. 7D, lanes 1 and 3). The Bax (DTM) protein was also
produced at similar levels (Fig. 7D, lane 2).
The abilities of the mouse HA-Bax and HA-Bax (DIGDE)
proteins to coimmunoprecipitate with the endogenous human
Bax protein in 293 were then compared. For these experiments,
immunoprecipitations were performed with anti-HA antibody
and the resulting immune complexes were subjected to SDS-
PAGE–immunoblot analysis using an antipeptide antiserum
specific for the human Bax protein (33). As shown in Fig. 7E
(lanes 1 and 3), human Bax protein coimmunoprecipitated
with the wild-type mouse HA-Bax protein but not with the
HA-Bax (DIGDE) protein. The endogenous wild-type human
Bax protein also coimmunoprecipitated with the HA-Bax (DTM)
protein (Fig. 7E, lane 2). Incubating the blot with the anti-HA
monoclonal antibody confirmed that equivalent amounts of the
HA-Bax and HA-Bax (DIGDE) proteins had been immuno-
precipitated (not shown). These findings thus confirm in mam-
malian cells the results of the yeast two-hybrid experiments
which suggested that the Bax (DIGDE) protein was incapable
of homodimerizing.
A TM domain is not required for targeting of Bax to mito-
chondria in mammalian cells. In yeast cells, the removal of the
TM domain from Bax resulted in loss of targeting to mitochon-
dria and loss of function. In contrast, the Bax (DTM) protein
retained nearly full activity as an inducer of apoptosis in Rat-1
cells. To explore the location of Bax (DTM) in mammalian
cells, this protein was expressed in 293 cells as a fusion protein
with the GFP(S65T) protein, a mutant form of GFP that has
stronger fluorescence properties than the wild-type protein
(21). Cells were also stained with a mitochondrion-specific
rhodamine-like dye to visualize these organelles. Examination
of these GFP(S65T)-Bax (DTM)-expressing cells by fluores-
cence confocal microscopy demonstrated the presence of the
GFP-Bax protein in the cytosol in a punctate pattern, sugges-
tive of organelle association (Fig. 8a). A similar pattern was
evident for the mitochondrion-specific stain as well (Fig. 8b).
Two-color analysis revealed colocalization of the GFP(S65T)-
Bax (DTM) protein and mitochondria (Fig. 8c). In contrast,
when the GFP(S65T) protein was expressed in 293 cells as a
control, the only green fluorescence observed was located dif-
fusely throughout the cytosol and did not colocalize with mi-
tochondria (Fig. 8d to f). Unlike in yeast cells, therefore, a TM
domain is not required for targeting of Bax to mitochondria in
mammalian cells, presumably because mammalian cells con-
tain endogenous Bax or other proteins with which the Bax
(DTM) protein can interact.
DISCUSSION
In yeast cells, the cell death process induced by Bax did not
resemble apoptosis, inasmuch as no evidence of nuclear frag-
mentation and chromatin condensation was evident by EM
and in that the DNA degradation which occurred in Bax-
expressing yeast cells was a late event that did not involve the
oligonucleosomal degradation pattern which classically occurs
in mammalian cells when induced to undergo apoptosis.
Though DNA ladders that can be detected by conventional
agarose gel electrophoresis are not necessarily seen in apopto-
tic cells (54, 74, 83), the morphological changes in nuclear
shape and chromatin condensation are essentially universal
features of apoptosis in mammalian cells but were not found in
Bax-expressing S. cerevisiae. Instead, the cell death process
induced by Bax in yeast cells resembled autophagy, with dis-
solution of the internal organelles and vacuolarization.
FIG. 6. Evaluation of cytotoxic function of Bax (DIGDE) and other mutants
in yeast cells. EGY191 cells were transformed with plasmids encoding the full-
length wild-type Bax protein or various Bax mutants (expressed as LexA fusions)
and plated onto histidine-deficient medium. Colonies were counted after incu-
bation at 308C for 4 days. The data shown were obtained from three experiments
(mean 6 standard deviation). Bax(AS) represents cells transformed with the
same pEG202 plasmid containing the bax cDNA subcloned in antisense orien-
tation. (B) The relative levels of the LexA fusion Bax and Bax mutant proteins
were determined by immunoblotting (30 mg) using anti-LexA antibody.
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It should be noted, however, that not all programmed cell
deaths (PCDs) occur with the classical features of apoptosis in
animal and plant species (64). For example, the death of in-
tersegmental muscle cells that occurs near the end of meta-
morphosis in the moth Manduca sexta involves the cell shrink-
age typically seen during apoptosis, but plasma membrane
blebbing, production of apoptotic bodies, and nuclear frag-
mentation do not occur (64). Furthermore, the only chromatin
condensation seen in these PCDs occurs in a punctate, focal
pattern; in apoptotic cells, by contrast, margination of con-
densed chromatin against the nuclear envelope is typically
observed. The PCD of muscle cells in the moth also does not
involve internucleosomal DNA cleavage (64). Similarly, PCD
of the stalk cells of sorocarps, multicellular fungus-like struc-
tures formed by the unicellular protist Dictyostelium discoi-
deum when grown under conditions of nutrient insufficiency or
overcrowding, involves cytoplasmic vacuolarization and cyto-
solic condensation similar to classical apoptosis but membrane
blebbing is absent, possibly because of the presence of a cell
wall. Nuclear fragmentation is also not seen during PCD of
these stalk cells, but multifocal chromatin condensation which
is distinctly different from the chromatin margination seen in
classical apoptosis is detectable by EM. These PCDs also occur
in the absence of DNA degradation that can be detected by
either routine agarose gel electrophoresis or pulsed-field gel
electrophoresis (10). Likewise, the PCD response induced by
pathogens in tobacco (the hypersensitive response) is associ-
ated with induction of endonuclease activities and genomic
DNA digestion, but the DNA fragmentation does not involve
the oligonucleosomal pattern of DNA cleavage or nuclear
morphological changes often seen in apoptosis (44). These
morphological and biochemical differences in PCD in various
plant and animal species argue that at least the distal portions
of the cell death pathways have diverged during evolution. It
therefore remains to be established whether more proximal
elements of these cell death pathways are conserved. For ex-
ample, while a family of cysteine proteases has been implicated
recently as major effectors of apoptosis in animal species (re-
viewed in reference 40), to date there is no evidence that plant
species rely on similar proteins for execution of their PCDs.
Regardless, from comparisons of PCD in various animal and
plant species, it is clear that the absence of oligonucleosomal
DNA fragmentation and nuclear fragmentation does not nec-
essarily preclude the possibility that the mechanism by which
Bax induces cell death in yeast cells is physiologically relevant
to mammalian cells, nor does it prove it.
Related to this issue of whether the cell death process in-
duced by Bax in yeast cells is physiologically meaningful for
mammalian cells is the observation that while Bcl-2 can block
cell death induced by numerous stimuli that result in apoptosis,
under some circumstances overexpression of Bcl-2 has also
been shown to prevent cell deaths that were clearly necrotic
rather than apoptotic in their morphological and biochemical
characteristics (28, 29, 66, 69). For example, necrotic cell death
induced in neuronal cell lines in vitro by agents that deplete
intracellular glutathione is blockable by Bcl-2, suggesting that
Bcl-2 family proteins may regulate a cellular process that leads
to apoptosis in some cases but necrosis in others (28, 29).
FIG. 7. Effects of Bax, Bax (DIGDE) and Bax (DTM) on apoptosis in Rat-1
and 293 cells. (A) Bax, Bax (DIGDE), and Bax (DTM) were subcloned into
plasmid pHA-Shin for expression as HA epitope-tagged proteins. Rat-1 cells
were cotransfected with pHA-Shin (control), pHA-Shin-Bax, pHA-Shin-Bax
(DIGDE), or pHA-Shin-Bax (DTM) and the b-galactosidase reporter plasmid,
pCMV-b-gal. Cells were fixed and stained with X-Gal 24 h after transfection, and
the number of blue cells (b-galactosidase positive) was counted by microscopic
examination (mean 6 standard deviation for triplicate transformations). (B) 293
cells were transfected with 7 mg of pcDNA3-HA-Bax, pcDNA3-HA-Bax (DTM),
pcDNA3-HA-Bax (DIGDE), or parental pcDNA3-HA plasmid DNA by a cal-
cium phosphate precipitation method. Approximately 36 h later, the floating and
adherent cells were pooled and stained with DAPI, and the percentage of cells
with nuclear fragmentation was determined (data representative of two experi-
ments). (C) Representative photographs of the transfected 293 cells used for
panel B, illustrating the nuclear fragmentation typical of apoptotic DAPI-stained
cells compared with normal cells with intact nuclei. (D and E) 293 cells were
transiently transfected with 20 mg of pcDNA3-HA-Bax, pcDNA3-HA-Bax (DTM),
pcDNA3-HA-Bax (DIGDE), or pcDNA3-HA (pShin-HA) parental plasmid
DNA, and ;60 h later, cell lysates were prepared. After normalization for total
protein content, lysates were either used directly (30 mg; D) or immunoprecipi-
tated (300 mg) with anti-HA monoclonal antibody (E) and then analyzed by
SDS-PAGE–immunoblotting using either anti-HA (D) or anti-human Bax (E)
antibody. The open arrowhead indicates positions of three-HA epitope-tagged
Bax, Bax (DTM), and Bax (DIGDE) proteins. The closed arrowhead indicates
human Bax protein. Detection was by an enhanced chemiluminescence method.
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Similarly, Bcl-2 and Bcl-XL can prevent cell death induced in
vitro by hypoxia, an insult typically considered to be a classical
inducer of necrotic cell death (15, 27, 67). Though much of the
cell death that occurs in the setting of hypoxia in vitro may be
due to apoptosis, some is clearly necrotic in its morphological
characteristics and is blockable by Bcl-2 and Bcl-XL (66). In
experiments involving transgenic mice which overexpress Bcl-2
in central nervous system neurons, Bcl-2 has also been shown
to significantly reduce hypoxia-induced cell death in vivo in
models of stroke, a situation that results in both apoptotic and
necrotic cell deaths (41). Finally, Bcl-2 can prevent necrotic
cell death induced by viral infection (69).
Taken together, therefore, these data indicate that Bcl-2
family proteins can regulate cell death pathways that do not
necessarily culminate in apoptosis. Furthermore, elements of
this cell death mechanism may be evolutionarily conserved
even as far back as yeast species, since the Bax protein can
induce death in the budding yeast S. cerevisiae and Bcl-2 can
rescue these cells from the cytotoxic effects of Bax. Bcl-2 has
also been shown to rescue mutant yeast strains with defects in
superoxide dismutase from the lethal effects of growth under
aerobic conditions (29), providing further evidence that at least
portions of the cell death mechanism regulated by Bcl-2 family
proteins may be operative in yeast cells. Moreover, we have
recently observed that the proapoptotic proteins Bax and Bak
have a lethal phenotype when expressed in the fission yeast
Schizosaccharomyces pombe and that Bcl-XL but not Bcl-XS
can rescue these cells from Bax- and Bak-mediated death (un-
published data). Thus, whatever the cell death mechanism
employed by Bax and other Bcl-2 family proteins in S. cerevi-
siae, it appears to be functional in S. pombe as well. It remains
to be determined whether this potentially conserved function
derives from the recently hypothesized function of Bcl-2 family
proteins as pore-forming molecules (50) rather than through
their functional or physical interactions with other conserved
proteins in yeast cells.
Cell suicide behaviors have been observed in a variety of
unicellular organisms, raising speculations that the cell death
mechanisms currently recognized as apoptosis and PCD in
multicellular organisms may have very primitive evolutionary
origins (reviewed in references 68, 81, and 85). For example,
some strains of Escherichia coli will activate the expression of
genes that trigger cell death when infected with bacterio-
phages. Moreover, many other examples of cell death exist in
unicellular bacterial species that could reasonably be classified
as suicide or programmed in that the cell is an active partici-
pant in its own demise and the death of individual cells affords
a survival advantage to other cells that derive from common
antecedents, including the cell deaths associated with (i) re-
striction-modification systems involving restriction endonucle-
ases and counteracting methylases, (ii) cell suicide following
DNA damage induced by irradiation or chemicals in bacteria
FIG. 8. GFP-Bax (DTM) protein colocalizes with mitochondria in 293 cells. 293 cells were transiently transfected with pS65T-Bax (DTM) (a to c) or parental pS65T
(d to f) plasmid DNA. After ;60 h, the cells were incubated with MitoTracker dye and analyzed by fluorescence confocal microscopy using appropriate filters for
visualization of green (A) or red (B) fluorescence, or both (C), resulting from the GFP(S65T) and MitoTracker molecules. Data are representative of the majority of
doubly stained cells.
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carrying colicin toxin genes, (iii) the sacrifice of mother cells
during sporulation of bacilli, and (iv) the death and subsequent
cannibalization of cells during fruiting body formation by myxo-
bacteria (reviewed in references 68, 81, and 85). Moreover, cell
death occurring with the classical features of apoptosis has also
been reported for some eukaryotic unicellular organisms, such
as Trypanosoma species, which have been shown to undergo
apoptotic cell death in response to high cell densities or insuf-
ficient nutrients (1, 79). Finally, the discovery that some PCD-
regulatory genes have homologs in both plants and animals
(such as the antiapoptotic gene dad-1) lends further weight to
the argument that some portions of the cell death machinery
may have evolved originally in unicellular organisms, before
the divergence of the plant and animal kingdoms (2). Though
several potential evolutionary advantages to having cell suicide
mechanisms even in unicellular organisms can be imagined,
defenses against viruses represent a particularly compelling
argument (reviewed in references 76, 77, and 81). Thus, when
a virus infects a yeast culture, for example, one mechanism for
limiting viral spread and thereby preserving the genomes of the
progeny of these unicellular organisms would be for the virus-
infected cell to commit suicide before viral replication can
occur. Elements of this defense mechanism then could have
been transferred to and embellished upon during evolution in
metazoans, where it again would have served the organism well
when confronted with viruses.
The finding that a membrane-anchoring domain is essential
for Bax function in yeast cells but expendable in mammalian
cells raises the possibility of differences in the way this death-
promoting protein functions in these two types of cells. It is
more likely, however, that in mammalian cells, Bax does not
require a TM domain for targeting to appropriate intracellular
membranes because of its ability to dimerize with endogenous
Bax and other Bcl-2 family proteins that are already integrated
into the outer mitochondrial membrane because of their TM
domains. In contrast to Rat-1 and 293 cells, we have observed
that removal of the TM from Bax abrogates its proapoptotic
function in some types of cells (unpublished observations).
Thus, differences between Bax (DTM) function in Rat-1 and
293 cells and in some other cell lines raise the possibility that
the efficiency with which Bax (DTM) targets to mitochondria or
other appropriate membrane compartments differs among cell
types. By analogy, it has been observed that the relative im-
portance of a TM domain in Bcl-2 varies widely among various
cell lines for its antiapoptotic function, with some cells display-
ing essentially no dependence, others showing partial depen-
dence, and still others exhibiting complete dependence on a
membrane-targeting domain (5, 23, 24, 52, 72). Taking these
data together with the data presented here, therefore, we spec-
ulate that either yeast cells lack homologous proteins to which
Bax (DTM) mutants can dimerize or the interaction of Bax
(DTM) with these yeast proteins is inefficient so that, on a
quantitative basis, far more Bax (DTM) protein production
would be required to observe a functional effect on cell viability
in yeast cells than in some types of mammalian cells.
In yeast and 293 cells, the wild-type Bax protein appeared to
be associated largely with mitochondria. We have also ob-
served by two-color immunofluorescence and by laser-scanning
microscopy that most of the Bax protein appears to be local-
ized to mitochondria in other human and mouse cells (unpub-
lished data). By analogy to other Bcl-2 family proteins (14, 24,
34, 36, 48), however, association with other intracellular mem-
branes is probably likely as well but may be underappreciated
because mitochondrial association would tend to concentrate
the immunofluorescence label into discrete foci and thus pro-
duce more intense signals. At issue, therefore, is the question
of whether mitochondrial association is essential for Bax func-
tion, as opposed to the possibility that integration into other
intracellular membranes suffices. It will be of interest in future
studies therefore to purposely target Bax to other nonmito-
chondrial membrane locations by fusion with appropriate tar-
geting sequences in an effort to determine whether mitochon-
drial association is essential.
In this regard, an important role for mitochondria in apo-
ptosis has come from experiments involving a cell-free apopto-
sis system wherein mitochondria were shown to be essential for
induction of apoptosis-like destruction of nuclei by cytosolic
extracts (51). In that study, nuclei derived from Bcl-2-over-
expressing cells were not protected from cytosolic extract-in-
duced destruction, suggesting that Bcl-2 protein associated with
the nuclear envelope was insufficient for preventing genomic
digestion and nuclear destruction. Moreover, Zamzami et al.
have recently reported that mitochondria isolated from pre-
apoptotic mammalian cells release proteinaceous factors that
can result in apoptotic-like destruction of naive isolated nuclei
in a cell-free system in vitro (87), and it has been shown
recently that cytochrome c may be one such mitochondrial
protein (38a). Again, nuclei isolated from Bcl-2-overexpressing
cells were not protected, despite evidence that nearly half of
the intracellular Bcl-2 protein is associated with the nuclear
envelope (36). The release of apoptotic factors from mitochon-
dria has been linked to the induction of permeability transition
(megapore opening) in mitochondria, which can be prevented
by overexpression of Bcl-2 (87). Given that yeast mitochondria
are also known to contain a similar channel (reviewed in ref-
erence 90), it is tempting to speculate the Bax may induce or
facilitate megapore opening in both mammalian and yeast
mitochondria, thereby leading to cell death. The recently de-
termined structure of the Bcl-XL protein, with its similarity to
pore-forming bacterial toxins, is also consistent with this hy-
pothesis (50). Perhaps analogous to the release of proteins
from the mitochondria of preapoptotic cells, the pore-forming
B subunit of diphtheria toxin is believed to provide a conduit
for the entry of the ADP-ribosylating A subunit across lysoso-
mal membranes into the cytosol (49). Consistent with this idea,
the induction of permeability transition in mitochondria has
been shown to result in release of matrix proteins (25). Of
further interest is the correlation between the location of the
Bcl-2 protein as determined by EM, which is enriched at the
junctional complexes of mitochondria (11, 36), and data which
suggest that the megapore is also associated with the junctional
complexes where the inner and outer membranes of mitochon-
dria come into contact (3). Experiments are in progress to
explore the relation of Bax and Bcl-2 to regulation of mito-
chondrial permeability transition in yeast and mammalian
cells.
Recently, Greenhalf et al. reported that Bax fails to exhibit
a cytotoxic effect in petite strains of yeast ([rho0] cells) which
lack mitochondrial DNA and that therefore are incapable of
accomplishing oxidative phosphorylation (17). This observa-
tion suggests a functional connection between mitochondria
and the ability of Bax to confer a lethal phenotype on yeast
cells. In our hands, however, Bax cytotoxicity was not impaired
in [rho0] yeast strains (unpublished data). Moreover, in the
system of Greenhalf et al., Bcl-2 required a TM domain for sup-
pression of Bax-mediated cytotoxicity, whereas in our hands
the Bcl-2 (DTM) protein was used successfully to inhibit Bax
lethality in yeast cells (this report and references 4, 19, and 61).
Though strain variations could potentially account for some of
these experimental differences, we have performed our analy-
sis of Bax in three different strains (EGY48, L40, and BF264-
15Dau) with similar results. In addition, previous studies have
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shown that mitochondrial DNA and oxidative phosphorylation
are not required for apoptosis (26). Mitochondrial DNA is also
not required for establishment of a membrane potential across
mitochondria or for induction of permeability transition (39).
Moreover, Bcl-2 can protect [rho0] cells from apoptosis (26).
Inasmuch as suppression of apoptosis by Bcl-2 has been shown
to be dependent at least in part on its ability to heterodimerize
with Bax (86), it would therefore appear that oxidative phos-
phorylation is not essential for Bax function in mammalian
cells. However, further analysis of the relevance of oxidative
phosphorylation to the cell death-promoting action of Bax in
yeast and mammalian cells is required before firm conclusions
can be drawn.
It has been speculated that Bax-Bax homodimers promote
cell death (70), but data which directly address this issue have
previously been unavailable. The loss of function of the Bax
(DIGDE) mutant seen here in both yeast and mammalian cells
suggests that homodimerization may indeed be required for
the cell death-promoting function of this protein. It should be
recognized, however, that the removal of these four amino
acids from the BH3 domain of Bax could have additional
effects on other aspects of Bax protein structure and function
which are unpredictable. The BH3 domain of Bax in which the
IGDE motif resides has been shown recently to be required for
Bax-Bax homodimerization, as well as for heterodimerization
with Bcl-2 and E1b-19kDa, whereas the BH1, BH2, and N-
terminal regions of Bax are expendable (18, 88). These other
regions of Bax (BH1, BH2, and N) were also not essential for
Bax function in yeast cells, thus lending further evidence to the
argument that Bax-Bax homodimerization may be critical for
its death-promoting activity in both yeast and mammalian cells.
Though the Bax (DBH1), Bax (DBH2), and Bax (DN) mutants
were not tested in mammalian cells, the proapoptotic effects of
similar mutants of the Bak protein have been examined by
using the same Rat-1 cell transient transfection assay system as
employed here (8). Those studies demonstrated that the region
of Bak where the BH3 domain resides was sufficient, in the
absence of BH1, BH2, or the N domains, to promote apopto-
sis, though for some mutants it was necessary to include a TM
domain. In addition, the proapoptotic Bcl-2 family protein Bik
contains a BH3 domain but lacks entirely sequences with ho-
mology to BH1, BH2, or the N domain, further suggesting that
the BH3 domain is particularly important for promotion of cell
death in mammalian cells (6).
Taken together, these observations suggest at least three
non-mutually exclusive models for how the BH3 domains of
Bax and similar proapoptotic proteins such as Bak and Bik may
regulate cell death (Fig. 9). First, this domain may be required
for homodimerization of Bax and similar proapoptotic pro-
teins, with the homodimeric forms of these proteins then
somehow interacting with other currently undiscovered pro-
teins involved in the cell death pathway or forming pores in
membranes directly upon dimerization or oligomerization.
Second, the BH3 domain may bind directly to some unknown
cell death effector protein, thus promoting cellular demise by
activating this downstream killer protein. In keeping with the
non-mutually exclusive nature of these models, the BH3 do-
main could accomplish this in monomeric form or (as we have
suggested here) may engage this killer protein only when
dimerized. Third, the BH3 domain could act as a decoy that
binds to Bcl-2, Bcl-XL, or other antiapoptotic members of the
Bcl-2 protein family, thus preventing them from interacting
with the endogenous Bax protein, thwarting the attempts of
Bcl-2 and Bcl-2-like proteins to homodimerize, or preventing
Bcl-2 and its functional homologs from binding to other pro-
teins whose interactions are critical for cell survival. To the
extent that further experimentation fails to reveal homologs of
Bcl-2 in yeast cells (thus far, no candidate exists), this third
model could be excluded as the sole explanation for Bax pro-
tein function but probably does play a role in mammalian cells
in which Bcl-2 or similar antiapoptotic proteins are expressed.
As evident from the models presented in Fig. 9, Bax may
employ multiple mechanisms for promoting cell death. In con-
clusion, the data presented here provide further evidence that
the BH3 domain of Bax plays a critical role in the mechanisms
by which this protein promotes cell death in both yeast and
mammalian cells and also raise the possibility that homodimer-
ization of Bax and targeting to mitochondrial membranes are
important facets of its function as well.
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14. González-Garcia, M., R. Pérez-Ballestero, L. Ding, L. Duan, L. H. Boise,
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